Letter to the Editor
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Jan 27, 2025; 17(1): 100968
Published online Jan 27, 2025. doi: 10.4254/wjh.v17.i1.100968
Hepatitis B virus infection and metabolic dysfunction associated steatotic liver disease: Rising pandemic with complex interaction
Ammara A Majeed, Amna S Butt
Ammara A Majeed, Amna S Butt, Department of Medicine, Aga Khan University Hospital, Karachi 74800, Pakistan
Author contributions: Majeed AA and Butt AS both had reviewed the article, performed literature search and written the letter; Butt AS has received the invitation for article; and all authors thoroughly reviewed and endorsed the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Amna S Butt, Associate Professor, Department of Medicine, Aga Khan University Hospital, Stadium Road, Karachi 74800, Pakistan. amna.subhan@aku.edu
Received: September 2, 2024
Revised: November 6, 2024
Accepted: December 2, 2024
Published online: January 27, 2025
Processing time: 127 Days and 18.6 Hours
Core Tip

Core Tip: Advancements and explorations in the understanding of underlying pathophysiology of concomitant hepatitis B virus (HBV) infection and metabolic dysfunction associated steatotic liver disease (MASLD) facilitates clinicians in managing patients with this complex interaction. Studies have shown various relationships and interactions between MASLD and HBV infection. Concomitant HBV infection and MASLD can result in increased HBV surface diversity and increased HBV variants which can potentially impact liver disease progression. Further research is warranted to better understand the mechanisms and optimize treatment strategies in patients with hepatic steatosis and HBV infection.